Noninvasive ventilation in COVID-19 patients aged ≥ 70 years-a prospective multicentre cohort study.

Détails

Ressource 1Télécharger: 35869557_BIB_6C00092709EA.pdf (1012.36 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_6C00092709EA
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Noninvasive ventilation in COVID-19 patients aged ≥ 70 years-a prospective multicentre cohort study.
Périodique
Critical care
Auteur⸱e⸱s
Polok K., Fronczek J., Artigas A., Flaatten H., Guidet B., De Lange D.W., Fjølner J., Leaver S., Beil M., Sviri S., Bruno R.R., Wernly B., Bollen Pinto B., Schefold J.C., Studzińska D., Joannidis M., Oeyen S., Marsh B., Andersen F.H., Moreno R., Cecconi M., Jung C., Szczeklik W.
Collaborateur⸱rice⸱s
COVIP Study Group
Contributeur⸱rice⸱s
Eller P., Joannidis M., Mesotten D., Reper P., Oeyen S., Swinnen W., Brix H., Brushoej J., Villefrance M., Nedergaard H.K., Bjerregaard A.T., Balleby I.R., Andersen K., Hansen M.A., Uhrenholt S., Bundgaard H., Fjølner J., Hussein AARM, Salah R., Ali YKNM, Wassim K., Elgazzar Y.A., Tharwat S., Azzam A.Y., Habib A.A., Abosheaishaa H.M., Azab M.A., Leaver S., Galbois A., Guidet B., Charron C., Guerot E., Besch G., Rigaud J.P., Maizel J., Djibré M., Burtin P., Garcon P., Nseir S., Valette X., Alexandru N., Marin N., Vaissiere M., Plantefeve G., Vanderlinden T., Jurcisin I., Megarbane B., Caillard A., Valent A., Garnier M., Besset S., Oziel J., Raphalen J.H., Dauger S., Dumas G., Goncalves B., Piton G., Barth E., Goebel U., Barth E., Kunstein A., Schuster M., Welte M., Lutz M., Meybohm P., Steiner S., Poerner T., Haake H., Schaller S., Schaller S., Schaller S., Kindgen-Milles D., Meyer C., Kurt M., Kuhn K.F., Randerath W., Wollborn J., Dindane Z., Kabitz H.J., Voigt I., Shala G., Faltlhauser A., Rovina N., Aidoni Z., Chrisanthopoulou E., Papadogoulas A., Gurjar M., Mahmoodpoor A., Ahmed A.K., Marsh B., Elsaka A., Sviri S., Comellini V., Rabha A., Ahmed H., Namendys-Silva S.A., Ghannam A., Groenendijk M., Zegers M., de Lange D., Cornet A., Evers M., Haas L., Dormans T., Dieperink W., Romundstad L., Sjøbø B., Andersen F.H., Strietzel H.F., Olasveengen T., Hahn M., Czuczwar M., Gawda R., Klimkiewicz J., de Lurdes Campos Santos M., Gordinho A., Santos H., Assis R., Oliveira AIP, Badawy M.R., Perez-Torres D., Gomà G., Villamayor M.I., Mira A.P., Cubero P.J., Rivera S.A., Tomasa T., Iglesias D., Vázquez E.M., Aldecoa C., Ferreira A.F., Zalba-Etayo B., Canas-Perez I., Tamayo-Lomas L., Diaz-Rodriguez C., Sancho S., Priego J., Abualqumboz EMY, Hilles MMY, Saleh M., Ben-HAmouda N., Roberti A., Dullenkopf A., Fleury Y., Bollen Pinto B., Schefold J.C., Al-Sadawi M.
ISSN
1466-609X (Electronic)
ISSN-L
1364-8535
Statut éditorial
Publié
Date de publication
22/07/2022
Peer-reviewed
Oui
Volume
26
Numéro
1
Pages
224
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Observational Study
Publication Status: epublish
Résumé
Noninvasive ventilation (NIV) is a promising alternative to invasive mechanical ventilation (IMV) with a particular importance amidst the shortage of intensive care unit (ICU) beds during the COVID-19 pandemic. We aimed to evaluate the use of NIV in Europe and factors associated with outcomes of patients treated with NIV.
This is a substudy of COVIP study-an international prospective observational study enrolling patients aged ≥ 70 years with confirmed COVID-19 treated in ICU. We enrolled patients in 156 ICUs across 15 European countries between March 2020 and April 2021.The primary endpoint was 30-day mortality.
Cohort included 3074 patients, most of whom were male (2197/3074, 71.4%) at the mean age of 75.7 years (SD 4.6). NIV frequency was 25.7% and varied from 1.1 to 62.0% between participating countries. Primary NIV failure, defined as need for endotracheal intubation or death within 30 days since ICU admission, occurred in 470/629 (74.7%) of patients. Factors associated with increased NIV failure risk were higher Sequential Organ Failure Assessment (SOFA) score (OR 3.73, 95% CI 2.36-5.90) and Clinical Frailty Scale (CFS) on admission (OR 1.46, 95% CI 1.06-2.00). Patients initially treated with NIV (n = 630) lived for 1.36 fewer days (95% CI - 2.27 to - 0.46 days) compared to primary IMV group (n = 1876).
Frequency of NIV use varies across European countries. Higher severity of illness and more severe frailty were associated with a risk of NIV failure among critically ill older adults with COVID-19. Primary IMV was associated with better outcomes than primary NIV. Clinical Trial Registration NCT04321265 , registered 19 March 2020, https://clinicaltrials.gov .
Mots-clé
Aged, COVID-19/therapy, Cohort Studies, Female, Frailty, Humans, Intensive Care Units, Male, Noninvasive Ventilation/adverse effects, Pandemics, Prospective Studies, Respiration, Artificial, Respiratory Insufficiency/therapy, COVID-19, Elderly, Intensive care unit, Noninvasive ventilation
Pubmed
Web of science
Open Access
Oui
Création de la notice
02/10/2022 22:18
Dernière modification de la notice
25/01/2024 7:37
Données d'usage